GENI.L Stock Analysis
GE
Uncovered
Genincode PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
GENinCode Plc engages in the risk assessment and prediction of cardiovascular disease. The company is headquartered in Oxford, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2021-07-22. The firm specializes in genetic risk assessment and prediction of cardiovascular disease thrombosis and familial hypercholesterolemia. Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Thrombo and Thrombo Incode Reproductive Health. Its geographic markets include Spain, Italy, France, Germany and the Rest of the World. The Company’s wholly owned subsidiaries include GENinCode S.L.U. and GENinCode U.S. INC.